Monday, December 11, 2017
Health

New drug shows promise as migraine headache preventive

Reporters and editors get dozens of emails and story pitches every day. But one recent news release from the American Academy of Neurology caught my attention immediately.

It was about a clinical trial involving a new drug for preventing migraine headaches. Even better, it's part of a new class of drugs specifically developed to prevent migraines. All the preventive medications currently available were first used to treat other health conditions.

In the new trial, patients reported fewer headache days each month, with almost no major side effects.

It was the best news to come along in years. Suddenly I was hopeful about getting relief from a painful condition that has dogged me for more than three decades.

My migraines started when I was in elementary school in Virginia. I used to call them a headache in my eye. Maybe that's why my parents kept taking me to opticians and buying me eyeglasses with sparkly pink frames and stars and poodles on the sides — they thought the headaches were caused by eye strain.

The glasses didn't help. But because the headaches were isolated and occurred just a few times a year, we didn't give them much thought. I don't remember taking so much as an aspirin for the pain or being taken to the doctor because of them.

It wasn't until I landed a new job and moved to Florida in 1985 that the headaches became much more frequent and debilitating. It took a while for me to eventually connect with a neurologist who told me I had migraines. By this time, I rarely woke without a headache.

I also noticed they could be triggered by hunger, alcohol, caffeine, citrus or changes in my sleep schedule.

My mistake was trying to manage the problem myself and not seeking treatment with a specialist sooner. I thought I just had headaches more often than other people — that the only thing to do was to take Tylenol. And when that didn't work, to just take more.

Eventually, I learned that taking too much pain medication made the pills less effective and caused even more headaches, known as rebound headaches. And, I learned that most people who have frequent migraines need to be on a daily preventive medication to reduce the need for pain relievers.

A daily preventive isn't something you take after a headache hits. It's taken every day, even on days without headaches, to prevent the attacks, lessen their number and to reduce the pain intensity of those that do break through.

According to the National Headache Foundation, migraines affect more than 30 million Americans, more women than men. About 3 million suffer chronic migraines — meaning a headache 15 or more days each month for three months or more, with eight of them being migranic in nature, lasting four or more hours.

As a chronic migraine headache sufferer, you're also most likely missing a lot of work or school or social activities, and are unable to perform some activities of daily living like grocery shopping, housekeeping, working out or shuttling children around.

"Preventives increase the number of days that you can work, socialize, participate in life," said Dr. Teshamae Monteith, a headache neurologist and chief of the headache division in the department of neurology at the University of Miami Miller School of Medicine. "Preventives can reduce the frequency and severity of attacks, make treatments, even over-the-counter ones, work better and generally make migraines easier to treat."

The most common preventives were originally intended to treat such health problems as high blood pressure, depression, epilepsy, even aging. They often come with bothersome, sometimes intolerable, side effects, including dry mouth, drowsiness, weight gain, constipation, mind fog, difficulty speaking or swallowing, changes in taste, tremors, nightmares and hallucinations.

I've had to abandon several preventives because of side effects. Others worked for a while and then, after a few years, stopped working.

Some patients find relief from a common cosmetic procedure.

"I have a lot of success treating patients with Botox. It's helpful for a good percentage of people," said Dr. Robert Vollbracht, a headache neurologist at Clinical Neurosciences of Tampa Bay based at Morton Plant Hospital in Clearwater.

Botox is best known for smoothing wrinkles and relaxing the "parenthesis" frown lines between the eyebrows. To treat chronic migraines, patients receive 31 injections of botulinum toxin around the head and neck. The injections are given every 12 weeks; it can take two or three rounds of treatment to get results.

Some patients find the shots painful but report getting relief for several months at a time. (Vollbracht says diluting the medication slightly can make the injections less painful.)

Doctors aren't sure why Botox works, but they think it does more than just relax the head and neck muscles. It may play a role in preventing the body from sending out pain signals during headaches. Still, it is the only FDA-approved drug for prevention of chronic migraines.

"I find that preventives work about 50 percent of the time. So it can take a lot of trial and error to find one that works for you," Vollbracht said. "It may take a combination of medications to get results." Or sometimes the dose just needs to be adjusted.

Patients need to understand, he added, that what doesn't work for you may work for someone else. You also have to give the medications time. It can take weeks or months to get relief.

The new medication that got my attention doesn't even have a name yet. It's known as TEV-48125 and is a monoclonal antibody, part of a new class of drugs that target and block a chemical in the brain called CGRP that increases during migraine headaches. TEV-48125 is manufactured by Teva Pharmaceuticals, and three similar drugs are currently in development.

In a study released earlier this month by Teva, some patients with chronic migraines reported relief within days of the first treatment. After a week, people on a low dose of the drug had an average of nine fewer hours of head pain, and those on a higher dose had 11 fewer headache hours. In the trial, reported in the journal Neurology, the drug was injected once a month for three months.

"This one from Teva is quite exciting," said Dr. Janice Maldonado, an assistant professor of neurology at USF Health based at the Neurology, Pain and Headache Clinic at Tampa General Hospital. She is not involved in the clinical trial.

"This takes into consideration the physiology of migraine," Maldonado said. "It's a carefully thought out approach to treatment that attacks the generator of the migraine itself. It should work."

Monteith, the Miami neurologist, is part of a clinical trial testing a similar monoclonal antibody manufactured by Eli Lilly and Co. for the treatment of cluster headaches. She thinks TEV-48125 looks promising too.

"It treats the root cause of migraines," she said. "It may also be safe for people with cardiovascular disease, but further study is needed to confirm that. That might be a bonus."

One of the key classes of drugs for stopping a migraine after it starts, the triptans, (Sumatriptan or Imitrex, Eletriptan or Relpax and Zolmitriptan or Zomig) can't be given to people with certain heart conditions or a heart attack or stroke history because of the effect they have on blood vessels.

The clinical trials continue, but doctors are hopeful the FDA could approve the first CGRP blocker by 2018.

What will it cost? It's hard to say, but some experts estimate the drug will run between $8,000 and $20,000 a year. Some monoclonal antibodies currently used to treat cancer, for example, cost as much as $50,000 annually. Getting insurance companies to cover such expensive drugs may be difficult and will take time. Copays could be high.

Scientists also need to know what the long-term health effects of using a CGRP blocker are and how the drug will perform when given to thousands of patients in large nationwide trials, instead of a few hundred patients at a handful of study sites.

Still, I can't help but be quietly excited. And, hopeful for the first time in years.

Times researcher John Martin contributed to this report. Contact Irene Maher at [email protected]

   
Comments
A boy shares the pain of being bullied - inspiring thousands to show him love (w/video)

A boy shares the pain of being bullied - inspiring thousands to show him love (w/video)

While fighting back tears, young Keaton Jones couldn’t stop asking one question: Why?"Just out of curiosity, why do they bully? What’s the point of it?" he asks his mother while in the passenger seat of a parked car. "Why do you find joy in taking in...
Updated: 2 hours ago
Legalization of marijuana for adults poses problems for people dealing with teens

Legalization of marijuana for adults poses problems for people dealing with teens

WESTMINSTER, Calif. — After Yarly Raygoza attended the drug prevention program at the Boys & Girls Club here last year, she used what she learned to talk a few friends out of using marijuana.The 14-year-old took the class again this year but worries ...
Published: 12/10/17
Millions gained coverage since Obamacare, but many are worse off as premiums soar

Millions gained coverage since Obamacare, but many are worse off as premiums soar

As open enrollment for Affordable Care Act coverage nears the deadline of Dec. 15, and Florida once again leads all states using the federal exchange at healthcare.gov, Heidi and Richard Reiter sit at the kitchen table at their Davie home and struggl...
Published: 12/10/17
A gift of hands: After loss, a man finds hope from healing ones (w/video)

A gift of hands: After loss, a man finds hope from healing ones (w/video)

ST. PETERSBURG — Francisco Piedra fixed his eyes on the man sitting beside him. His name was Richard Brown, and in his hands he held Piedra’s new ones.The prosthetics were black and plastic. Each one took about 20 hours to build from a 3D printer. Pi...
Published: 12/08/17
The solar eclipse burned a crescent wound on a woman’s retina. She wasn’t wearing proper glasses.

The solar eclipse burned a crescent wound on a woman’s retina. She wasn’t wearing proper glasses.

Like so many others, 26-year-old Nia Payne wanted to view of August’s historic solar eclipse but didn’t have a pair of protective glasses. She walked outside on Staten Island and glanced at the sun - 70 percent was covered - for about six seconds bef...
Published: 12/08/17
At St. Joseph’s Women’s Hospital, death of a colleague inspires ‘hats with heart’

At St. Joseph’s Women’s Hospital, death of a colleague inspires ‘hats with heart’

TAMPA — Brittany Weatherby didn’t know how to crochet when she started her job as a registered nurse at St. Joseph’s Women’s Hospital, and she never dreamed of learning how.Maybe her grandma used to, she tried to remember, but Weatherby never really ...
Published: 12/08/17
How kids’ books can introduce a lifetime of fitness

How kids’ books can introduce a lifetime of fitness

When I became a parent last year, it seemed likely my marathon running days were behind me.Running had made me a grittier person. It had given me the very specific self-assurance that comes from calmly enduring 26 miles on foot, a quality that would ...
Published: 12/08/17

Mayo Clinic Q&A: seek attention for mole that bleeds; a look at lung restoration

DON’T WAIT: BLEEDING MOLE SHOULD BE EVALUATED BY A DOCTOR Should I see a health care provider for a mole that bleeds occasionally?Yes. Although it may not be serious, a mole that bleeds is a possible sign of melanoma, a rare but serious skin cancer t...
Published: 12/08/17
Lightened Shepherd’s Pie comforting, quick

Lightened Shepherd’s Pie comforting, quick

When the weather gets cooler, we want to tuck into comfort food in our home. Doing a recipe makeover on a tasty-but-less-than-healthy dish is one of my favorite challenges. Today, I’m taking on a wintertime classic with my Lightened Shepherd’s Pie. T...
Published: 12/08/17
Green Salad With Pumpkin Vinaigrette celebrates holiday season

Green Salad With Pumpkin Vinaigrette celebrates holiday season

By MELISSA D’ARABIANSummer may officially be the season of green salads, but wintertime versions have advantages that make them worth exploring. The cooler weather seasonable greens are hearty and darker green, which makes them nutrient-rich. And, th...
Published: 12/08/17